Poor Prognosis of Acute Myeloid Leukemia with FIP1L1- PDGFRA Fusion Gene in 27-Year-Old Male Treated with Tyrosine Kinase Inhibitors and Allo-HSCT

Zofia Spyra-Górny1*, Agnieszka Barchnicka2, Ewa Bodzenta2, Bożena Jaźwiec3 and Sebastian Grosicki1

1Department of Clinical Hematology and Cancer Prevention in Chorzów, Medical University of Silesia in Katowice, Poland
2Department of Clinical Hematology, Municipal Hospital in Chorzów, Poland
3Department of Hematology, Medical University in Wrocław, Poland

^*Correspondance to: Zofia Spyra-Górny 

 PDF  Full Text Case Report | Open Access

Abstract:

Acute Myeloid Leukemia (AML) with FIP1L1-PDGFRA fusion gene is a group of uncommon myeloid neoplasms. FIP1L1-PDGFRA positive AML is considered to have a good prognosis when using tyrosine kinase inhibitors in the course of treatment. Hereby we report a case of a 27-year-old male with FIP1L1-PDGFRA positive eosinophiliaassociated AML, resistant to imatinib, dasatinib as well as intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation. The course of our patient's treatment is not consistent with the reports of most authors.

Keywords:

Cite the Article:

Spyra-Górny Z, Barchnicka A, Bodzenta E, Jaźwiec B, Grosicki S. Poor Prognosis of Acute Myeloid Leukemia with FIP1L1-PDGFRA Fusion Gene in 27-Year-Old Male Treated with Tyrosine Kinase Inhibitors and Allo-HSCT. Ann Clin Case Rep. 2021; 6: 2031..